A Blue-Chip Starter Portfolio: GlaxoSmithKline plc, Royal Dutch Shell Plc And BHP Billiton plc

How do GlaxoSmithKline plc (LON:GSK), Royal Dutch Shell Plc (LON:RDSB), BHP Billiton plc (LON:BLT) and the UK’s other seven industry giants shape up as a starter portfolio?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Every quarter I take a look at the largest FTSE 100 companies in each of the index’s 10 industries to see how they shape up as a potential “starter” portfolio.

The table below shows the 10 industry heavyweights and their current valuations based on forecast 12-month price-to-earnings (P/E) ratios and dividend yields.

Company Industry Recent share price (p) P/E Yield (%)
ARM Holdings Technology 1,037 29.9 0.9
BHP Billiton (LSE: BLT) Basic Materials 1,249 18.8 6.4
British American Tobacco Consumer Goods 3,415 15.6 4.7
GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) Health Care 1,322 15.7 6.1
HSBC Holdings Financials 570 10.5 5.9
National Grid Utilities 817 13.8 5.4
Rolls-Royce Industrials 870 14.3 2.9
Royal Dutch Shell (LSE: RDSB) (NYSE: RDS-B.US) Oil & Gas 1,807 12.2 6.6
Vodafone Telecommunications 230 39.7 5.1
WPP Consumer Services 1,426 14.4 3.2

Historically, to get a feel for overall value, I’ve tracked the average P/E and yield of the “portfolio”, but excluding ARM with its typically lofty technology-sector valuation. However, for the past 18 months — since its mega-sale of Verizon Wireless — Vodafone’s valuation has also been anomalously high.

The table below shows the average portfolio P/E and yield at my quarterly review dates, including Vodafone (columns two and three) and excluding Vodafone (columns four and five).

  P/E Yield (%) P/E Yield (%)
July 2015 17.2 5.1 14.4 5.2
April 2015 17.2 4.9 14.9 4.8
January 2015 15.8 4.8 13.5 4.8
October 2014 15.0 4.7 13.1 4.6
July 2014 14.8 4.7 13.2 4.5
April 2014 13.6 4.6 12.8 4.6
January 2014 13.6 4.5 12.7 4.5
October 2013 12.2 4.7 12.1 4.7
July 2013 11.8 4.7 11.9 4.6
April 2013 12.3 4.6 12.4 4.4
January 2013 11.4 4.9 11.7 4.6
October 2012 11.1 5.0 11.1 4.7
July 2012 10.7 5.0 10.7 4.7
October 2011 9.8 5.2 9.8 5.0

My rule of thumb for the group of companies is that an average P/E below 10 is bargain territory, 10-14 is decent value, while above 14 starts to move towards expensive.

Last quarter I highlighted the growing disconnect between P/E and yield, suggesting:

“It may be that we’ll see a period of little or no dividend growth among the heavyweights (or even a rebasing of some dividends) to bring the yield down to a level that better reflects the high P/E and a low interest-rate environment in which other assets are yielding very little”.

This is starting to happen, although the average yield currently remains high. Since my April review, GlaxoSmithKline has announced it is pegging its dividend at an unchanged 80p a share for the next three years, while Shell has suggested its dividend may be flat at $1.88 for the next two years.

Nevertheless, I’d say the visibility these two companies have given us on their dividends and their high yields (Glaxo, 6.1% and Shell 6.6%) make them attractive for long-term investors at current price levels. Glaxo expects to return to earnings growth in 2016, guiding on annual growth for the period 2016-20 of mid-to-high single digits. Shell’s in-progress acquisition of BG Group should also drive earnings growth further down the line.

Miner BHP Billiton is another company where the short-term outlook is uninspiring, but the longer-term prospects much brighter. Billiton’s P/E of 18.8 is high, but, counterintuitively, high P/Es for miners can signal good times ahead for the share price and low P/Es the reverse. Three years ago, Billiton’s P/E was just 7.6 at a share price of 1,806p; the shares are now trading at 1,249p. Billiton’s current yield of 6.4% is also attractive, although the dividend may be vulnerable to the same lack of near-term growth as Glaxo and Shell, or even a re-basing.

Elsewhere, ARM, National Grid and HSBC, which I highlighted for you last quarter, continue to look attractive. ARM’s current P/E has dipped below 30 for the first time since I’ve been tracking the shares. National Grid’s P/E and yield are at value levels not seen since my October 2013 review. HSBC continues to have the lowest P/E of all 10 companies and a well-above-average yield.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline, HSBC and ARM Holdings. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After a positive Q4 update, is the Vistry share price set to bounce back?

The Vistry share price has been falling sharply as a result of cost issues in its South Division. But the…

Read more »

Investing Articles

Is it game over for the Diageo share price?

The Diageo share price is showing as much spirit as an alcohol-free cocktail. Harvey Jones is wondering whether he should…

Read more »

Young Caucasian girl showing and pointing up with fingers number three against yellow background
Investing Articles

3 key reasons why AstraZeneca’s share price looks a steal to me right now

AstraZeneca’s share price has fallen a long way from its record-breaking level last year, which indicates that I may be…

Read more »

Investing Articles

Here’s how investors could aim for a £6,531 annual passive income from £11,000 of Aviva shares

As a stock’s yield rises when its price falls, I'm not bothered by Aviva shares’ apparent inability to break the…

Read more »

Investing Articles

3 million reasons why earning a second income is more important than ever

With AI posing a threat to UK jobs, our writer considers ways to earn a second income by investing in…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

With an 8% yield, is the second-largest FTSE 250 stock worth considering?

Our writer considers the value of the second-largest stock on the FTSE 250 with a £4bn market cap and a…

Read more »

Close-up of British bank notes
Investing Articles

10%+ dividend yields! 3 top dividend shares to consider in 2025!

Investing in these high-yield UK dividend shares could deliver a huge passive income for years to come. Royston Wild explains…

Read more »

Bearded man writing on notepad in front of computer
Investing Articles

Greggs’ share price tanked last week. So I bought more!

Could Greggs be one of the FTSE 250's best bargains following its share price slump? Royston Wild thinks so, as…

Read more »